WELCOME BY EFMC PRESIDENT RUI MOREIRA
Welcome to our first MedChemBioWatch for 2023!
After a year 2022 marked by the return of presential conferences, we start this year with a positive onlook in a successful year to come. Our activities will continue to expand with new opportunities to recognise excellence and merits: the EFMC-WuXi AppTec Award for Excellence in Chemical Biology and the Symeres PhD Prize for Excellence in Chemistry in Life Sciences Research.
Our meeting calendar will be busy, but it also offers more chances to meet each other and network with our peers, and I look forward meeting you in person at one or the other occasion.
This is only possible due to the involvement and perseverance of many members and collaborators. I am certain that we are all looking forward to the many opportunities EFMC offers for networking, connecting, and advancing medicinal chemistry and chemical biology...so, make sure you keep tuned!
Finally, on behalf of the EFMC, let me wish you a successful and healthy year.
EFMC YEARBOOK 2023 IS AVAILABLE
The official EFMC Yearbook 2023, "Medicinal Chemistry and Chemical Biology in Europe" is a valuable resource for those interested in quickly finding information on all things related to EFMC, such as the activities and composition of Member Societies, Corporate Members and the activities and events of EFMC and its working groups.
The Yearbook is available as an electronic version only. For an optimal reading experience of the Yearbook, we recommend using Chrome, Microsoft Edge, or Firefox.
READ THE PDF VERSION
EFMC-YSN ANNOUNCES THE CREATION OF THE SYMERES PHD PRIZE FOR EXCELLENCE IN CHEMISTRY IN LIFE SCIENCES RESEARCH
The "Symeres PhD Prize for Excellence in Chemistry in Life Sciences Research" is an EFMC-YSN Partner Prize given annually, with the aim to recognise outstanding research in medicinal chemistry and chemical biology, executed by early career researchers during their thesis work.
Upon application, the submission will be peer reviewed and the 10 best candidates will be invited to the Symeres facilities in Nijmegen, The Netherlands to present their work. The prizes will consist of a diploma and a cash prize of 1000€ for the winner, 600€ for the runner-up and 400€ for the third place. The winner will also be invited to deliver an oral communication at the EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS).
The 2023 winner will also receive a free registration and a 500€ travel grant to attend both the IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2023) and the 10th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS 2023) which will take place in Zagreb, Croatia on September 3-7 & September 7-8, 2023.
The eligibility criteria are as follow:
- PhD students (up to 12 months before the end of PhD) and postdocs (up to three years after PhD) in medicinal chemistry or chemical biology.
- Applicants should be European residents, having received or being currently enrolled in a PhD from a European university.
More info and applications on www.efmc.info/symeres-phd-prize
Deadline for submission: March 15, 2023
This Prize has been established with the support of Symeres.
EFMC AWARDS & PRIZES – DEADLINE IS APPROACHING (JANUARY 31, 2023)
The deadline to apply for one of the 2023 EFMC Awards or Prizes is quickly approaching!
- EFMC-WuXi AppTec Award for Excellence in Chemical Biology
- EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia
- EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry
- EFMC-Young Scientists Network PhD Prize
Nomination deadline is January 31, 2023!
The Award will be given for outstanding research in the field of chemical biology as defined by EFMC in The Chemical Biology-Medicinal Chemistry Continuum: EFMC’s Vision1, ChemBioChem 2021, 22, 2823-2825 link (free access).
The award will be conferred biennially on the occasion of the European Federation for Medicinal chemistry and Chemical Biology International Symposium on Chemical Biology (EFMC-ISCB 2023), scheduled to take place in Basel, Switzerland on November 16-18, 2023.
To acknowledge and recognise outstanding young medicinal chemists and chemical biologists (≤ 12 years after PhD) working in European industry and academia.
For the 2023 edition, the prize-winners will be invited to give an oral communications at the IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2023), scheduled to take place in Zagreb, Croatia on September 3-7, 2023. Two additional nominees will also be identified and acknowledged as most meritorious runners-up.
To recognise excellence and accomplishment in postgraduate research.
The prize will consist of a diploma, 500€ and an invitation to deliver an oral communication at the EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS). The 2023 winner will also receive a free registration and a 500€ travel grant to attend both the IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2023) and the 10th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS 2023) which will take place in Zagreb, Croatia on September 3-7 & September 7-8, 2023.
The “literature spotlight” section of the newsletter will bring you a summary of recently published research in a concise and accessible way. Multiple thematics from different journals will be highlighted thanks to the valuable contribution of members of the EFMC working groups.
This contribution will focus on the recently published article on the “Elucidation of the bridging pattern of the Lantibiotic pseudomycoicidin” by Kathrin Janssen et al., published in ChemBioChem.
Pseudomycoicidin is an antibiotic peptide expressed by Bacillus pseudomycoides and is recognised as a potential therapeutic for the treatment of antibiotic-resistant gram-positive bacteria. Following expression, the peptide undergoes a series of post-translational modifications which result in the formation of several disulfide and lanthionine bridges. The product is a complex, criss-crossed protein structure with antibiotic properties. While the activity of these peptides are highly compelling, the true structure of many ‘lantibiotics’ remain unknown.
The authors set out to elucidate the structure of pseudomycoicidin, deciphering the peptide’s post-translational bridge network, like a game of intramolecular sudoku. Pseudomycoicidin was already known to contain six cysteine residues, giving rise to four lanthionine bridges and one disulfide bridge in the lantibiotic structure. The authors rationalised that four of the eight hydroxy-containing residues in the peptide must therefore undergo dehydration to form cysteine-reactive Michael acceptors. These would become the sites for lanthionine bridging.
Using MALDI-TOF-MS and tandem mass spectrometry to measure fragmentation patterns, the authors studied the peptide in the presence or absence of a reducing agent, leading to the localisation of the disulfide bridge position. They next performed an alanine scan and treated the resulting peptide with the dehydrating enzyme PseM. Mass spectrometry allowed the number of dehydration reactions in the mutant peptide to be counted. Wherever three dehydrations had occurred rather than four, the authors had identified a position for lanthionine bridging. Fragmentation patterns were also contrasted between the wild-type and mutant peptides to identify new sites of fragmentation. The appearance of a new fragmentation cluster in the mutant was reasoned to be the location of a lanthionine bridge in the wild-type peptide.
Through a process of elimination, the authors were able to propose an elaborate double ring system for pseudomycoicidin. The resulting globular structure hints towards pseudomycoicidin functioning as a disruptor of bacterial cell wall biosynthesis, though more studies on this mode of action are required. Interrogating the structure-activity relationships of these complex polycyclic peptides may highlight new strategies for combatting antibiotic-resistant pathogens.
Read the article
EFMC-YSN EDITORIAL PUBLISHED: THE FACETS OF DIVERSITY: THE EFMC PERSPECTIVE
The EFMC-YSN proudly announces the release of their editorial on “The Facets of Diversity: The EFMC Perspective”, recently published in ChemMedChem, by Dr. Chiara Borsari, Brieuc Matagne, Dr. Kristina Goncharenko, Prof. Rui Moreira & Dr. Yves P. Auberson.
Diversity in science refers to cultivating talent, while promoting full inclusion across the community. In medicinal chemistry and chemical biology, it enhances creativity and encourages contributions from multiple perspectives, leading to better decision making and broader scientific impact. The European Federation for Medicinal chemistry and Chemical biology (EFMC) embraces and promotes diversity, to ensure representation of all talents, and enable equality of opportunity through fairness and transparency. EFMC has historically paid continuous attention to diversity in terms of culture, geography and equilibrium between academia and industry, with over the last few years a focus on increasing gender balance, aiming at a fair representation of the scientific community and equal opportunities independently of gender. EFMC promotes cultural diversity as it reinforces openness and mutual respect. All scientific organizations of a scope compatible with its remit are welcome within EFMC, where their members benefit from a welcoming, psychologically safe, and stimulating environment. Herein, we describe the state of diversity within the EFMC, how the situation has evolved over the years and where diversity should be further encouraged.
Read the article
GET TO KNOW CHRISTIAN TYRCHAN, ASTRAZENECA, SWEDEN
In this edition, our #Iamamedicinalchemist is the computational chemist Christian Tyrchan from AstraZeneca, Sweden.
Get to know him better by reading our interview below.
How did you get interested in Computational Chemistry?
I always had a keen interest in natural sciences, especially in how the body works on the molecular level. For example, how do cells/ organs operate; how do xenobiotics manipulate our being. For me, the main focus point was clearly chemistry, therefore I started to study chemistry at the University of Cologne. I worked on my Diploma thesis at the Institute of Pharmacology (University of Cologne), this being my first steps into medicinal chemistry.
During an Erasmus stay at the University of Bern working at the organic synthesis of PNA, I got the first time in contact with computational chemistry in modelling different PNA/DNA complexes. To follow up on the computational part I did my PhD-Thesis at the Department for Biochemistry (University of Cologne), “Development of a distance- and direction dependent knowledge based potential for the prediction of protein thermostability”. Hooked by computational chemistry I moved more into the area of cheminformatics during my PostDocs.
This landed me a position at the global chemoinformatic group at AstraZeneca.
Tell us more about your current position at AstraZeneca?
I currently work as a teamleader for the computational chemistry group in R&I at AstraZeneca. We are currently eight people in addition to a handful of students, graduates and PostDocs. I am always willing to discuss possibilities of doing a Master Thesis within the group, collaborations and visiting students.
We all work in pre-clinical drug discovery projects as the computational chemistry responsible, chemistry lead or project co-lead. The way we are organized is that we follow a project from idea to the clinical candidate, being exposed to all the challenges and stages of such an endeavour. Curiosity, resilience and scientific rigor are key skills to have, besides solid knowledge of medicinal & computational chemistry. We apply a wide range of methods, software and tasks for the different phases. Having a background in cheminformatics my research interest resolves around machine learning and its challenges in the application in drug discovery.
What we would like to achieve is to find a substance which is able to have a positive effect on a given condition. How we do this is like solving the rubics cube, without looking at it and the cube constantly changing colors with swapping fields.
What do you consider your greatest achievement in your scientific career?
I am very proud of the science we do within the team and with Master and Graduate students as PostDocs or visiting PhDs. Scientifically I consider our publication in the field of cheminformatics introducing ChemistryConnect a milestone – collating at this scale SAR data was at that time industry leading. In terms of medicinal chemistry the work in PI3K was the most satisfying, resulting in several publications and clinical candidates. From a machine learning perspective I am very happy about my collaboration with Marwin Segler 2016 leading to REINVENT the first RNN molecular generator with impact across the industry in the field of AI lead drug discovery.
What advice would you give to someone who wants to move forward with studies in the field?
Tips: be resilient, honest, respectful, curious, understand the intend and read Richard Feynman´s speech of cargo cult science. If you are interested in medicinal chemistry synthesis chemistry excellence is a must, but also start looking into pharmacology and physical organic chemistry. The later is also true for computational chemistry. Instead of synthesis excellence you should be able to program to understand the methods behind the tools. Always be prepared and able to question them.
What is the most embarrassing thing you have done in the lab while doing experiments, e.g. explosions?
I did a lot of mistakes and stupid things while learning and I wouldn’t consider them as embarrassing. One good lesson was in the beginning of my studies during practical work. Heating up a glass pipette to change its form (forgot the reason why), took it out of the flame and waiting a couple of seconds and asking “is it still hot?” while touching it. It was hot and I have still the scar on my finger.
What are your recommendations for a book, podcast, website, blog, YouTube channel or film?
The blog In the Pipeline from Derek Lowe. Modern Physical Chemistry from EV Anslyn and Dougherty. I have several must-read papers for newcomers in my team.
Which field of medicinal chemistry do you consider the most promising for the future?
In terms of computational chemistry and medicinal chemistry it will be automated/autonomous design, make and test cycles, including high throughput experimentation.
14th EFMC-YSN MEDCHEMBIOONLINE | SUCCESSFUL STORIES OF WOMEN IN SCIENCE: INSPIRING CAREER PATHS
In its 14th edition of the now renowned MedChemBioOnline series, the EFMC Young Scientists Network offers an exciting programme around “Successful Stories of Women in Science: Inspiring Career Paths”.
The event will take place on February 28 between 16:30 and 18:30 CET. Have a look at the programme:
- Addressing Underexplored Anti-infective Targets
Prof. Anna K. H. Hirsch (Helmholtz Institute for Pharmaceutcial Research Saarland, Germany)
- Science Communication is not only for the public
Dr Elodie Chabrol (Freelance Science Communicator, France)
- Round Table Discussion: "Challenges and Opportunities for Women in STEM"
- Prof. Anna K. H. Hirsch (Helmholtz Institute for Pharmaceutcial Research Saarland, Germany)
- Dr Elodie Chabrol (Freelance Science Communicator, France)
- Prof. Zaneta Nikolovska-Coleska (University of Michigan, United States)
- Panelists to be announced
More info and registration on www.medchembio.online. Registration to the event is free and open to all.
Interested in becoming the exclusive sponsor of the event? Reach out to us at email@example.com.
IT FINALLY CLICKS! A NOBEL PRIZE IN CHEMICAL BIOLOGY IN 2022
When K. Barry Sharpless published his seminal treatise on what he termed “Click Chemistry” in Angewandte Chemie in 2001, the response of the chemical world was silence, except perhaps for a few derisive snickers. The idea that functional simplicity and thermodynamic impetus could be selection criteria for reactions in any field that required libraries of small molecules just didn’t click to a synthetic community infatuated with complexity. But good ideas bubble up. Indeed the chemical and biological world immediately began to take Sharpless’ ideas to heart, creatively employing the few reactions initially identified by Sharpless as having the properties necessary to count as click reactions.
Following this conceptual paper, the discovery of the copper catalyzed version of the azide-alkyne cycloaddition (independently and contemporaneously by Sharpless and Meldal) provided the architype for what the best click reactions could do – and the rapid explosion in application of this reaction across chemical disciplines demonstrated how much of a pent-up demand there was for such simple and predictable chemistry. As a perfect embodiment of the click concept, it is fitting that the azide-alkyne cycloaddtion is now colloquially known as the “click reaction”. And so the Sharpless and Meldal portion of the prize relates to the formulation of the click chemistry concept (Sharpless) and the discovery of the Cu-catalyzed version of the azide-alkyne cycloaddition (Sharpless and Meldal).
Bertozzi also introduced new ideas and a new variation of the azide-alkyne cycloaddition, but her motivations were firmly rooted in the nascent field of chemical biology. She recognized that chemical reactions that could reliably operate within the biological milieu (and without damaging native biological processes) would constitute an especially important tool in biology research. Reactions like these – which would operate orthogonally to biological chemistry – would offer the opportunity to do selective chemistry in living cells and organisms, thereby offering chemical control or chemical monitoring of biological functions. In the early 2000’s the chemical toolbox that would constitute these aptly dubbed “bioorthogonal reactions” was small and crude (oxime formation, Staudinger ligation). Bertozzi, however, would change that with the development of a strain-promoted version of the azide-alkyne cycloaddition. Whereas the copper-catalyzed variant of the azide-alkyne cycloaddition worked great in the round-bottom flask, or in cell lysates, it fell short in living cells or whole organisms because free copper is typically toxic to cells. Even in cases where it might be tolerated, adding large amounts of copper to any cellular or organismal experiment would undermine the trust in the biological significance of any measurements (in other words the click is not bioorthogonal since copper is deeply embedded in biology). The development of a strain-promoted version of the azide-alkyne cycloadditon provided a truly bioorthogonal ligation that could be used in cells and organisms. Today, the Bertozzi variation of the azide-alkyne cycloaddition is in widespread use in chemical biology and the ideas she formulated has stimulated synthetic chemists to build a large repertoire of bioorthogonal reactions.
This was an unusual Nobel prize because it constituted elements of concept building (click chemistry, bioorthogonal chemistry) as well as fundamental reaction development (Cu-catalyzed and strain promoted azide-alkyne cycloaddition) under a single banner. Us practicing chemical biologists should commend the Nobel committee for their flexible thinking in rewarding all the different ways scientific thought and discovery can shape a field.
NEWS FROM THE DIVISION MEDICINAL CHEMISTRY & CHEMICAL BIOLOGY, ROYAL NETHERLANDS CHEMICAL SOCIETY (KNCV-MCCB)
The dept. of Chemistry and Pharmaceutical Sciences, VU University Amsterdam announce the Nauta Lecture and Nauta Master Class 2023: The role of type 2 inflammation in air pollutant particle effects in chronic lung disease by Dr. Martin Leonard (UK Health Security Agency).
The lecture will take place on Friday February 3rd 2023 from 16:45 to 17:45 Auditorium at the Vrije Universiteit Amsterdam. No registration required.
The Nauta Master Class Series: Mechanisms of pulmonary susceptibility to injury and disease given by Dr. Martin Leonard (UK Health Security Agency) will cover fundamental concepts in lung susceptibility to injury and disease, including how genetic and environmental factors interact to influence outcome.
The course is intended for Masters and/or PhD students, but anybody with an interest in the topic are more than welcome. No fees required, but we would ask you to register as limited in-person places are available. The course will also be live-streamed via Zoom.
Register for free here: online registration
#MedChemCASES - SEMINAR BY THE DIVISION OF MEDICINAL CHEMISTRY OF THE GERMAN CHEMICAL SOCIETY (GDCH)
The MedChem Division of the German Chemical Society (GDCh) would like to invite you to the next #MedChemCASES online seminar which will be held on January 24 by Dr Stefan Gradl (Bayer, Germany).
The topic of the webinar will be “Discovery and structure activity relationships of BAY 2666605: PDE3A-SLFN12 complex inducer for cancer therapy”.
Velcrin compounds are small molecules which act as molecular glues to form a PDE3A-SLFN12 complex. This complex formation induces apoptosis in cancer cells expressing elevated levels of PDE3A and SLFN12 (de Waal et al., Nat Chem Biol 2016; Wu et al., J Bio Chem 2020). Unlike traditional targeted therapies that leverage dependencies created by genomic alterations in cancer cells, velcrins instead kill cancer cells by a gain-of-function mechanism dependent on stimulation of SLFN12 RNase activity by complex formation with PDE3A (Garvie et al., Nat Commun 2021).
Based on in-vivo tool compounds which were discovered by hit-to-lead optimization from a phenotypic screen (Lewis et al., ACS Med Chem Lett 2019), the team set out to optimize the properties of the tool compounds. While already showing excellent potency and in-vivo efficacy in various tumor models, the compounds were only approximately tenfold selective against PDE3A when compared to their cell killing activity. PDE3A/B activity most notably influences cardiohemodynamics and inhibition of PDE3A/B was to be reduced to generate a larger safety window. Co-crystallization of analogs with PDE3A showed the binding mode of the velcrin class and changes in the solvent exposed region of the PDE3A binders led to steep activity changes in complex formation and cell killing. Careful optimization of the ratio of cell killing to PDE3A activity while optimizing DMPK and safety pharmacology led to the discovery of BAY 2666605.
BAY 2666605 has recently entered a First-in-Human study (NCT04809805) in patients with advanced solid tumors that co-express PDE3A and SLFN12, including melanoma, ovarian cancer, and sarcoma. We will discuss the discovery and structure activity relationships of BAY 2666605.
NEWS FROM THE BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR (BMCS) OF THE ROYAL SOCIETY OF CHEMISTRY (RSC)
The BMCS is happy to provide a report of its recent 16th BMCS Postgraduate Symposium and announces several upcoming events.
- 7th RSC-BMCS Mastering Medicinal Chemistry
- 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets
- 10th SCI/RSC Kinase Symposium on Inhibitor Design
- 3rd Synthesis in Drug Discovery and Development
- 3rd RSC Anglo-Nordic Medicinal Chemistry Symposium
BMCS POSTGRADUATE SYMPOSIUM XVI – ANNOUNCEMENT OF THE WINNERS
The 16th BMCS biological and medicinal chemistry symposium was held on Friday 9th December 2022 at the Medical Sciences Teaching Centre at the University of Oxford and attracted 41 abstracts. There were over 150 registered attendees who heard three plenary lectures and 7 young researcher lectures. There were also 17 poster presentations and the quality of the science presented was yet again extremely high
I am pleased to announce that the prize awardees are as follows:
||Nicola Ashman from the University of Cambridge for her talk on ‘Peroxide-Cleavable Linkers for Antibody-Drug Conjugates’
||Jennifer Carter from the University of Oxford for her talk on ‘The development of small molecule inhibitors of the essential Leishmania bromodomain BDF5’
Clara Gathmann from the University College London for her poster titled ‘Predicting the Thermodynamics of Water in the KRASG12C Binding Site’
||Harry Wilders from the University of Strathclyde & GSK for his poster titled ‘A high-throughput-chemistry, direct-to-biology approach to discover novel reactive fragments targeting SARS-CoV-2
Rebecca Stevens from University of Strathclyde & GSK was voted by delegates as winner of the ‘Participant’s Prize’ for her poster titled ‘Novel Cyclosporin-like molecules inhibit the antiviral restriction factor IFITM3 to enhance stem cell gene therapy’
The organising committee are grateful to all those companies which provided sponsorship for this meeting and to the exhibitors, without which it would be difficult to run as a free-of-charge event. We would also like to acknowledge the generosity of the University of Oxford for hosting this event
7th RSC-BMCS Mastering Medicinal Chemistry
22nd March 2023, Burlington House
Synopsis: Mastering Medicinal Chemistry VII is the latest in an ongoing series of conferences intended to provide expert advice and guidance to new practitioners in the field of drug discovery. It has been said that “there are two types of drug discovery programmes: those that hit serious problems and those that are going to hit serious problems”. Anticipating and preparing for such problems thus accelerates the delivery of new medicines: this event will feature presentations from experienced ‘drug-hunters’ in both industry and academia, who will talk about the challenges faced in modern drug discovery and will share best practice common to all successful medicinal chemists.
7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets
27th and 28th March 2023, Wellcome Genome Campus, Cambridge
Synopsis: Ion channels are important targets for therapeutic intervention due to their extensive roles in human physiology and the pathophysiology of disease. Many successful drugs targeting this gene family have been discovered for diseases such as hypertension, epilepsy and neuropathic pain.
This symposium, the 7th in an ongoing series, will showcase the most recent advances to aid the design of new ion channel therapeutics and promote interaction between scientists with a shared interest in the field of ion channel drug discovery.
10th SCI/RSC Kinase Symposium on Inhibitor Design
9thand 10th May 2023, SCI, London, UK
Synopsis: With more than 70 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 10th SCI/RSC symposium on kinases will encompass plenary lectures on emergent topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including new screening approaches, brain penetrant kinase inhibitors, induced protein degradation, allosteric inhibitors and kinase inhibition for immuno-oncology will be covered, along with views and perspectives on the future of kinase inhibitor research
3rd Synthesis in Drug Discovery and Development
23rd – 24th May 2023, Virtual
Poster abstract closing date is 22nd February, 2023
Synopsis: Synthesis is at the heart of drug discovery and development. The industry has increasingly demanded higher quality clinical candidates and has sought to exploit less druggable biological targets. Densely functionalised small molecules with a high degree of synthetic complexity are often the result of these demands. Successful programmes therefore require the application of innovative synthesis in all stages of discovery and development. The medicinal chemist’s toolbox is also enhanced by the introduction of novel bioisosteres, often made available only through the application of new synthetic methods. This symposium aimed to celebrate the crucial role of synthesis in the success of drug discovery and development
3rd RSC Anglo-Nordic Medicinal Chemistry Symposium
13th-16th June 2023, Hotel Comwell Borupgaard, Snekkersten, Denmark
The call for abstracts will close on 31st January 2023 (oral) and 4th May 2023 (poster)
Synopsis: Organised with Nordic affiliations, the scientific programme will feature themed lectures, focusing on medicinal chemistry and related technologies and disciplines across a range of drug targets and modalities. A distinguishing feature of this symposium is the collegiate style which encourages an atmosphere of information sharing and learning.
THIS NEWSLETTER IS KINDLY SPONSORED BY
ISSUE SPONSORED BY
Biological and Medicinal Chemistry Symposium March 6-8
ACS Publications, with the University of Bonn, is excited to present an in-person symposium featuring editors of its high-impact journals. Registration is free and includes three days of keynotes from world-renowned scientists, networking sessions, and a poster session!
EFMC ORGANISED EVENTS
April 23-26, 2023
Oegstgeest, The Netherlands
17th EFMC Short Course on Medicinal Chemistry
June 10-13, 2023
Boston, United States
ACSMEDI-EFMC Medicinal Chemistry Frontiers
September 3-7, 2023
IX International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC)
September 7-8, 2023
10th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS)
November 16-18, 2023
EFMC International Symposium on Chemical Biology (EFMC-ISCB)
EFMC SPONSORED EVENTS
May 21-24, 2023
IX European Workshop in Drug Synthesis (EWDSy)
June 13-16, 2023
3rd RSC BMCS Anglo-Nordic MedChem
July 5-7, 2023
57th International Conference on Medicinal Chemistry (RICT 2023)
June 19-21, 2023
Santiago de Compostela, Spain
VIII SEQT Summer School
July 2-6, 2023
European School of Medicinal Chemistry (ESMEC)
Applications Scientist, Schrödinger, FRANCE
PostDoc position in Medicinal Chemistry, Institut Pasteur de Lille, FRANCE
Various jobs opportunities, Sygnature Discovery, UNITED KINGDOM